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Summary A clinical trial conducted according to a schedule of interim analyses written into the protocol, and
stopped according to a predetermined rule, is known to statisticians as a sequential clinical trial. This
methodology is becoming more widely used in trials concerning life-threatening diseases because of its ability
to adjust the sample size to the emerging information on treatment efficacy. When treatments under
comparison differ appreciably, small samples will be sufficient; for more subtle differences larger numbers of
patients need to be recruited. Sequential methods have already been used in certain cancer clinical trials, and
they are especially appropriate for such studies.
In this paper the principles of sample size determination are reviewed, and the essential aspects of designing
sequential trials are described. The necessity for a special form of statistical analysis following a sequential trial
is explained, and the consequences of early or late stopping on the analysis are investigated. Compromises
which have to be made between the formal requirements of theory and the practical realities of trial conduct
are discussed.
Because of the lethal and insidious nature of the disease, the
ethical issues of clinical research are especially prominent in
cancer trials. It is in the interests of future cancer patients
that potential new therapies be subjected to extensive clinical
testing on large numbers of subjects so that even modest
advances over standard treatments can be identified and
quantified. Unfortunately, amongst the substances and proce-
dures tested will be many that confer no benefit and some
which do actual harm. It is in the interests of patients in a
clinical trial that ineffective or harmful treatments be tried on
as few people as possible before their nature is discovered.
This is the fundamental dilemma of clinical research in
cancer and in other life-threatening diseases.
A well-planned clinical trial will have a predetermined
sample size calculated to fulfil some power requirement (see
the second section). It is desirable that as the trial progresses,
a Data and Safety Monitoring Committee assesses the emer-
ging evidence and stops the trial if one of the treatment
groups is evidently experiencing an inferior pattern of sur-
vival. However, if the trial does stop as a result of an
intervention of the Data and Safety Monitoring Committee,
then statistical calculations performed by conventional
methods will be invalid.
The purpose of this paper is to describe designs for sequen-
tial clinical trials in which the sample size depends on the
accumulating patient outcomes. Although the application of
sequential methods to clinical trials goes back to Kilpatrick
and Oldham (1954), and to the work of Armitage (1975),
recent advances in both methodology (Whitehead, 1992a)
and computer software (Whitehead & Brunier, 1989) have
widened the range of their applicability and made implemen-
tation far easier than previously. It must be remarked that
only one point of view and one approach to sequential
clinical trials will be presented in this paper. The field is an
area of lively debate amongst statisticians, and several other
approaches are available. Some of the alternatives will be
mentioned in the penultimate section. The book edited by
Peace (1992) describes applications of a wide variety of
sequential procedures, Geller and Pocock (1987) offer guide-
lines for practitioners, and Pocock (1992) and Machin (1992)
present the issues of stopping clinical trials in non-technical
language. The methods of this paper have been applied to a
trial in lung cancer (Jones et al., 1982; Whitehead et al.,
1983; Newman et al., 1985), to a trial in leukaemia (Storb et
al., 1986) and to a trial in AIDS (Montaner et al., 1990)
amongst others. A current Medical Research Council trial in
renal cancer (MRC Urological Working Party, 1991) has also
been designed following this approach.
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Before proceeding to the main part of the paper, some
comments will be made on terminology. In this paper the
term 'sequential clinical trial' will refer to a trial planned to
have one or more interim comparisons of the treatment
groups, and with a prespecified rule to determine from the
result of each comparison whether the trial should be stop-
ped. The trial will be designed to achieve a certain power,
and the analysis will take into account the schedule of inspec-
tions in order to retain its frequentist properties. Thus hap-
hazard and unplanned looks are excluded, as are trials plan-
ned as fixed sample, but with interim looks imposed without
adjustment for the consequent loss of power. (Of course in
some cases the loss of power is so trivial to make their
exclusion rather fussy.)
The interim analyses may be frequent and many or seldom
and few. In the latter case they take place after observation
of large groups of deaths, and so the procedure could
accurately be described as 'group sequential'. However, the
latter term is most usually used to refer to a class of methods
similar to those introduced by Pocock (1977) and O'Brien
and Fleming (1979). Pocock's procedure certainly qualifies as
a sequential design under the definition given here. Strictly,
the O'Brien and Fleming design should be modified by a
slight increase in maximum sample size in order to compen-
sate for loss of power, before qualifying. The designs des-
cribed here are different in detail from Pocock's and O'Brien
and Fleming's, but not in principle.
Sample size determination
In a conventional design, the sample size is predetermined
and specified in the protocol. It is helpful to review how this
is done, before turning to sequential designs. The simple
context of a trial comparing one experimental treatment with
a control will be assumed. Patients are randomised between
the two treatments. The primary efficacy response is the time
from randomisation to death. The sample size is deduced
from a power requirement, as explained below.
A standard form of power requirement is illustrated by the
following example. Suppose that on a standard therapy used
as a control, patients with inoperable lung cancer have only a
50% chance of surviving for 6 months. A worthwhile thera-
peutic advance would be to increase this 6 month survival
rate to 65%. If these values hold true, then statistical
significance at the 0.05 level should be found with probability
0.90. A conventional power calculation shows that the trial
should collect information on 186 deaths. More precisely 186
events are required, where an event may be a cause-specific
death, or may include other adverse effects besides death. We
shall continue to write simply of 'deaths'.
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The mathematics so far is relatively reliable. If the six
month survival rates on control and experimental treatments
are 50% and 65% respectively, and if in the trial 186 deaths
are observed, then the probability of obtaining significance at
the 0.05 level is 0.90 with good accuracy. But what if the 6
monthly survival rate on control is not 50%? In fact the
absolute values of the survival rates are not essential features
of the sample size calculation. It is their relative values which
matter. If the 6 month survival rates on control and experi-
mental treatments are 50% and 65% respectively, then the
ratio of hazards for the population of patients on the experi-
mental relative to those on the control will be 0.62. The latter
can now be viewed as the target survival improvement, and a
more general statement of the power property of the trial is
as follows. If the ratio of hazards is 0.62 and 186 deaths are
observed, then the probability of obtaining significance at the
0.05 level is 0.90. The hazard ratio specified above is less
than one, indicating a reduced hazard on the experimental
treatment. An implicit assumption is that any reduction of
hazard will occur uniformly for all times after entry to the
trial; thus the experimental treatment will have the same
magnitude of effect on short-term survival, medium-term
survival and long-term survival. This assumption is one of
proportional hazards, and it underlies most sample size cal-
culations and analyses of survival data. The same hazard
ratio of 0.62 would follow from other specifications of 6
month survival rates. If the control and experimental group
survival rates at 6 months were respectively 40% and 57% or
60% and 73% or 70% and 80%, then in each case the
hazard ratio would be 0.62, and observation of 186 deaths
would achieve the required power. A formula linking
specified survival rates with the hazard ratio is given in the
Appendix.
The assumption of proportional hazards should not be
made lightly. There are many reasons, sometimes apparent at
the planning stage, why it may not be true. Non-
proportionality causes problems for both fixed-sample and
sequential designs. However, proportional hazards are
assumed in this paper, although alternative approaches are
considered briefly in Section 5.
The difficulty in setting a predetermined sample size for a
trial studying survival lies in translating a requirement for
186 deaths into a required number of patients. How many
patients should be recruited in order that we observe 186
deaths and for how long should they be followed up? For
this purpose absolute values of survival rates are required,
and not just a hazard ratio. If survival rates can be
anticipated, then the corresponding sample size and duration
can be calculated. These will be written into the protocol.
For example, if the survival rates at 6 months in the control
and experimental groups were 50% and 65% respectively,
hazards of death were constant over time, and ten patients
were recruited each month then, the required 186 deaths
should accrue from recruiting 240 patients over 2 years and
following them up for a further 6 months. Notice how many
idealising assumptions have been required to make this
prediction. If death rates turn out to be lower than
anticipated, then fewer than 186 deaths will be observed
amongst the specified number of patients and the trial will be
underpowered.
It can be concluded that the sample size which is written
into a cancer trial protocol is not a definitive and infallible
figure. The sample size calculation is an essential part of the
protocol, but the resulting trial has probability 0.90 of detec-
ting a treatment advantage only when specified population
hazard ratio is present, and that only when population death
rates have been accurately forecast (or at least not underes-
timated).
Sequential clinical trials
In a sequential clinical trial, the sample size is not determined
in advance. In its place a stopping rule is written into the
protocol. The rule will be chosen to satisfy the same power
requirement as would be used to determine sample size. For
example it might be specified that if the hazard ratio is 0.62,
then significance at the 0.05 level should be detected with
probability 0.90.
As the data accumulate, periodic inspections will be made.
At each inspection a statistic measuring the observed survival
advantage of the experimental treatment over control (Z) will
be calculated, together with a statistic measuring information
gathered so far (V). A plot of Z against V will be maintained.
The form of these statistics is given in detail in Whitehead
(1992a). For survival data, Z is (one form of) the logrank
statistic, and can be expressed as the observed number of
deaths in the control group minus the number of deaths
expected assuming no difference between treatments. If the
experimental treatment shows the better survival record then
the excess of deaths will be in the control group, and Z will
be positive. If the experimental treatment shows the worse
survival record then Z will be negative. Approximately, V is
equal to one quarter of the number of deaths, but its exact
form adjusts for imbalances in sample size and in the pattern
of entry to the two treatment groups and so is to be prefer-
red. The plot of Z against V will tend to rise if the experi-
mental treatment is superior, to fall if the experimental
treatment is inferior, and to proceed horizontally (with ran-
dom fluctuations) if there is no treatment difference. Inspec-
tions, and plottings of Z against V, continue until some
stopping rule is satisfied.
Figure 1 shows four possible stopping rules. For each, the
process of inspecting the data and plotting Z against V
continues until one of the boundaries is crossed. If the bold
solid upper line is crossed, then it can be concluded that the
experimental treatment is superior to the control at the
significance level 0.05. If the solid lower line is crossed, the
conclusion is that the experimental treatment is inferior to
the control at significance level 0.05. If the broken middle
boundary is crossed, then no significant difference can be
claimed. Also shown is a graph of the expected amount of
information, V, at termination (EVT). This is roughly pro-
portional to the expected number of deaths at termination,
and even more roughly indicative of final sample size. The
plot is against a measure of advantage of the experimental
treatment (6 as defined in the Appendix). All designs satisfy
the same power requirement and are drawn to scale. Of
course, significance levels other than 0.05, and powers other
than 0.90 can be accommodated.
Figure l(a) is an idealisation of a fixed-sample (that is,
non-sequential) design. It is an idealisation, because instead
of fixing the sample size itself, the final value of V is fixed. As
V is approximately equal to one quarter of the number of
deaths observed, continuing the trial until a specified number
of deaths have been observed would be equivalent. This is
the only way to ensure that a non-sequential design achieves
the required power, although it is rarely explicitly done in
practice. (Sometimes informed adjustments are made to the
target sample size in view of apparent low event rates.)
The properties of the other designs are shown in the
diagrams. All will end quickly, with a positive conclusion, if
the experimental treatment is much better than control re-
sulting in a steeply rising plot of Z against V. This can be
seen from the low values of EVT at the right hand sides of
the graphs in Figures l(b), (c), and (d). For more modest
improvements, larger sample sizes are likely, although (with
the exception of the restricted procedure (d)) economy
relative to the fixed sample design (a) can be anticipated
whatever the magnitude of the therapeutic effect. When there
is no treatment difference, designs (b) and (c) offer clear
sample size reductions: see the low values of EVT in the
central portions of the graphs in Figures 1(b) and (c). The
triangular test (b) does not seek to distinguish between the
case in which the experimental treatment and the control are
equally effective and the case in which the experimental
treatment is worse. Thus small samples are sufficient
whenever the experimental treatment is worse. It is, however,
a test against the two-sided alternative (a two-tailed test),
because very early stopping on the lower boundary is
unlikely if there is no treatment difference and so can lead toINTERIM ANALYSES 1181
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Figure 1 Some trial designs and their corresponding expected terminal amount of information (V) at termination: (a) fixed sample,
(b) triangular, (c) double triangular, (d) restricted procedure.
the conclusion that the experimental treatment is significantly
worse than the control. Design (b) is suitable for an experi-
mental treatment which, due to cost or toxicity, will only be
considered further if it offers a clearly demonstrated
therapeutic advantage.
The final analysis
When a sequential trial has stopped, an analysis will be
conducted. A P-value will be calculated, and the magnitude
of the treatment effect, as measured by the hazard ratio, will
be estimated. A confidence interval for the hazard ratio will
be found. These calculations should not use formulae
developed for fixed-sample size studies. To see why not,
consider a trial which has stopped because of a crossing of
the upper boundary, with the conclusion that the experiment-
al treatment is superior. Stopping because the experimental
happens to be ahead, means that a conventional P-value will
overstate the significance of the results, and a conventional
estimate of hazard ratio will overestimate the magnitude of
the treatment difference.
Underlying all conventional statistical analyses is the con-
cept of an ordering of all potential datasets arising from the
trial, according to the degree to which they indicate that the
experimental treatment is superior to the control. We can say
that a dataset which would indicate experimental superiority
more strongly than another dataset according to such an
ordering, is more positive. One particular dataset has been
observed. The P-value P1 against the one-sided alternative
that the experimental treatment is superior is defined as the
probability of observing a more positive dataset than the one
observed by chance alone (that is when treatments are
equivalent). When P1 <1, it can be doubled to give the more
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z usual P-value against the two-sided alternative of treatment
difference. In the remainder of this section, P-values will
concern the two-sided alternative. Estimates and confidence
intervals can also be defined in terms of the ordering of
potential datasets. After a fixed-sample study datasets result-
ing in a larger measure of advantage of experimental over
control (a larger value of Z) are taken to be more positive.
After a sequential trial terminating on the upper boundary,
any dataset leading to earlier stopping on the upper boun-
dary (a smaller value of V) may be regarded as more
positive. The calculations used to produce the required P-
values, estimates and confidence intervals are different from
those used after a fixed-sample trial, but their meaning and
interpretation are unchanged.
Figure 2 illustrates these analyses for a triangular test. The
top diagram shows a particular trial outcome, with the plot
of Z against V shown as a continuous path (see Section 5),
ending on the upper boundary. The lower diagrams indicate
the P- value and confidence interval for hazard ratio corres-
ponding to this outcome. Also shown are the P-values and
confidence intervals for all possible trial outcomes in which
the upper boundary is crossed. The maximum possible value
of V is denoted by Vmax. Notice that if the plot of Z against
V exits the triangle at the very tip (a most unlikely event)
then P will be equal to 0.05 and the confidence interval will
have an upper limit of 1. Any earlier crossing of the upper
boundary will result in P<0.05 and a confidence interval
entirely below 1. Early crossing of the upper boundary will
result in an analysis which is highly significant (P very small)
and in a confidence interval which although wide, is well
removed from 1 (no treatment effect). Although the
confidence interval is wide it does not seem ethical to allow
patients to continue to be randomised to the control just to
estimate with accuracy how much worse it is. Once such a
large treatment difference is evident, the absolute properties
of the experimental treatment remain of interest (and can be
observed in an uncontrolled study), but the merits relative to
control are of less interest. Later stopping results in P-values
closer to 0.05 and to narrower confidence intervals. Exiting
the triangular region at the very tip is extremely unlikely: if it
were to occur then we would have P = 0.05 and a confidence
interval only slightly wider than that from an equivalent fixed
sample study.
Implementation of sequential methods in practice
It is evident that no clinical trial will be inspected con-
tinuously, and yet the stopping rules illustrated in Figure 1
appear to presuppose this. In practice inspections of the data
will occur periodically, with frequencies varying between once
a week and once a year depending on the resources and need
to safeguard patient safety. Figure 3 shows how a triangular
test can be modified for discrete inspections. The internal
boundaries, indicated by broken lines, become the operative
stopping rules. Stopping is made more likely to compensate
for missed opportunities for stopping between inspections.
Because of their shape, the internal boundaries are called
Christmas tree boundaries. Similar adjustments can be made
to the designs shown in Figures 1(c) and (d). It is not
necessary to specify in advance the timings of inspections in
order to use this method, although their timings should not
be influenced by the observed evidence of treatment
difference inherent in the values of Z. It is not possible to
draw the Christmas tree boundaries at the start of the trial as
their shape emerges in response to the pattern of information
available at interim analysis. In some clinical trials it is
undesirable to stop very early because the large sample
assumptions underlying the statistical analysis are not yet
valid, and because results based on a small sample size would
not be persuasive. The first inspection of the data can be
delayed relative to the subsequent schedule in order to make
such premature stopping impossible.
Good data flow is an essential pre-requisite for successful
application of sequential methods. It is unnecessary for com-
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Figure 2 Analysis of a sequential clinical trial: how the P-value
and the 95% confidence interval for hazard ratio vary with the
final amount of information.
plete case record books to be available at each interim
analysis: only details of date of entry, survival or date of
death and of essential prognostic factors and treatment
assignment are required. Sometimes these are completed on
detachable sheets within the case record book and are trans-
mitted and processed separately.
The methods described can be used to monitor responses
other than survival times. In particular, binary (success/
failure) responser, ordered (good, moderate, poor, very poor)
responses, normally distributed quantitative responses and
counts can all be dealt with. Randomisation to experimental
and control treatments can be made in a 3:1, 2:1 or 1:2 ratio
(or any other) rather than 1:1. Stratified sequential analysis,
allowing for factors such as centre, stage of cancer at diag-
nosis or histological type of tumour, is possible. Adjustments
for continuous covariates such as age or white blood count
can be made.
When a clinical trial concerns a cancer which can be
rapidly lethal, it is sensible to continue to recruit patients
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looks, showing the Christmas tree boundaries.
until the stopping criterion is met. Sometimes the treatment
of interest will be ongoing chemotherapy. When the trial is
stopped patients will no longer be required to receive study
medication, and doctors are likely to alter the treatment of
many of them, particularly those who were randomised to
the less successful treatment. No new valid data can be
accrued in such a trial. Alternatively, the treatment of
interest may be applied for only a few days or weeks follow-
ing randomisation. This would be the case for surgical tech-
niques or radiotherapy. After stopping the trial, deaths
would continue to be reported, from patients already rec-
ruited and still following the regimen laid down in the pro-
tocol. The trial is said to overrun. Trials with overrunning
can be analysed within the sequential methodology. It is
possible, but unlikely, that the final plotted point incor-
porating all of the extra data lies again within the continua-
tion region of the study. Nevertheless the trial has stopped
and it is still likely to be significant. This issue is discussed at
length in Whitehead (1992b).
A cancer being studied might not be rapidly lethal, with
median survival times being 5 years or more. In such a
situation a sequential trial might be set up with a recruitment
period of 3 years (say) and a follow up period of 5 years.
Only in the case of a very large treatment difference apparent
early during treatment would sequential monitoring lead to
stopping during the recruitment period, thereby preventing
some patients being exposed to a substantially inferior treat-
ment. However, it is more likely that early stopping and
publication becomes possible during the follow-up period,
allowing the results to influence both clinical practice and
further research years earlier than with a trial of fixed dura-
tion.
There is sometimes a reluctance to terminate a cancer
clinical trial showing no sign of an advantage for the experi-
mental treatment, or even showing a disadvantage, on the
principle that 'something might turn up'. This is understan-
dable when the biological action of the therapy is such that
only long term benefit can be expected. Indeed, in the case of
toxic chemotherapy, short term disadvantage can be
anticipated, later to be outweighed by long term advantage.
The assumption of proportional hazards mentioned at the
end of the first section, would not be valid. In such a case a
clear target should be set: to improve survival rates after 1
year, 2 years or maybe 5 years, (choose only one of these!).
Sequential designs to detect such postponed benefit have not
yet been developed although the problem is currently being
explored. However, consider a situation in.which no case for
postponed benefit is made when the protocol is prepared.
Interim results indicate no treatment difference, or worse:
excess mortality on the experimental treatment. It then seems
foolhardy or even callous to suggest persistence on the
grounds that 'something might turn up'. It is a principle
which could be maintained indefinitely, to the detriment of
subjects in the study.
In some clinical trials, the research question can be stated
clearly at the outset. It may be 'Does the experimental
therapy reduce hazard throughout the time following treat-
ment?', or 'Does the experimental therapy improve survival
beyond 2 years after treatment?'. If the assumptions underly-
ing the question are verified by the trial data, and the ques-
tion is clearly answered, then its findings are likely to be
authoritative. On the other hand, in some cases the forms of
the survival patterns being compared are unclear at the
outset. They will eventually be compared in many ways -
overall, short-term only, long-term only, cause specific, by
subgroup, and so on. If only a few of these comparisons
show an advantage for the experimental treatment, then the
results will be more controversial - the problems of testing
multiple hypotheses suggested by the data are well-known. It
may be that further trials are needed to verify hypotheses
generated by the first trial.
One advantage of sequential over fixed-sample designs has
already been mentioned: although validity of the power
requirement in both cases depends on the proportional
hazards assumption being appropriate, for sequential designs
it is not necessary to know the pattern of survival on indivi-
dual treatments. Furthermore, interim analyses allow the
proportional hazards assumption to be checked during the
trial, and perhaps to be abandoned, with a revised trial
objective replacing interest in the hazard ratio. The effects of
such checks on trial properties is a topic which requires
methodological investigation.
Perhaps the most difficult case for a sequential design to
cope with is that of a treatment with short-term survival
benefit, later overturned by long-term disadvantage. If this
behaviour is unforeseen, a sequential trial may stop early,
recommending the new treatment on the grounds of the
observed short-term benefit. However follow-up should be
continued on the patients recruited, and this might motivate
a further trial directed specifically at long-term effects.
A sequential design will only operate effectively if it is
accepted and understood by all scientific participants in the
trial. The trial statistician needs to acquaint investigators
with the way in which the stopping rule is to operate, and of
the consequences of the rule. Often a statistical supplement
to the protocol will be prepared.
The inspections of the data could be conducted by a
statistician reporting to a Data and Safety Monitoring Com-
mittee. The investigators themselves will only be told when
an inspection has taken place, and whether the conclusion is
to stop or continue. Emerging details of the sample path, as
shown in Figure 3, will not be circulated.
It is possible that the Data and Safety Monitoring Com-
mittee may wish that the trial be terminated even before the
stopping boundaries are reached, for example because of a
large imbalance in the incidence of adverse events other than
death. It is also possible that they see good reason for
proceeding beyond the official stopping time, for example
because reduced toxicity compensates for poorer survival
times. Such decisions have their counterparts in the early
stopping or extension of a fixed-sample clinical trial. Their
ethical necessity must be allowed to override the inaccuracies
they inevitably bring to the statistical analysis. The value of a
sequential design, carefully discussed with the Data and
Safety Monitoring Committee beforehand, is that stopping
for reasons other than a boundary crossing in the sequential
design is made far less likely. The sequential design is a far
better model of the Committee's intentions than is a fixed-
sample design.
An objection sometimes raised to the use of sequential
designs is the need to specify funding requirements in
advance. In fact, during the course of many fixed-sample
trials, low accrual rates, high drop-out rates and unexpected
delays and complications can add to both duration and cost.
Perhaps the real difficulty is in facing up to these uncertain-
ties from the outset.
Implementation of sequential methods in clinical trials is
greatly eased by use of a computer program such as PEST
(Planning and Evaluation of Sequential Trials: Whitehead
and Brunier, 1989). The necessary calculations for design,
monitoring and analysis, for survival studies and for other
response types are all included.1184 J. WHITEHEAD
Alternative approaches to sequential investigation
Extensive reviews of sequential methodology suitable for
clinical research are given in Chapter 6 of Whitehead (1992a)
and by Jennison and Turnbull (1990). The earliest methods
to be applied extensively in clinical trials were the 'group
sequential' methods of Pocock (1977) and of O'Brien and
Fleming (1979). Pocock (1982) discusses improvements to his
1977 procedure, but these seem to have been overlooked by
practitioners. These methods require that inspections of the
data are conducted according to a regular pattern. In a
survival study this means that the number of new deaths
observed at each inspection is to be a constant. More flexible
extensions of the 'group sequential' approach are provided
by the 'a-spending function' method of Lan and DeMets
(1983).
A completely different view of the philosophy ofinferential
statistics as a whole is provided by the Bayesian school.
Bayesian analyses do not quote P-values or confidence limits,
but instead make probability statements concerning unknown
parameters such as the hazard ratio. Such probability
statements combine subjective opinions held prior to the
collection of clinical data, with the results of the trial. One
consequence of the Bayesian approach is that their analyses
are not affected by the use of stopping rules. Bayesian
sequential designs are described by Berry (1989) and Freed-
man and Spiegelhalter (1989) and are discussed by
Whitehead (1993).
Conclusion
In this paper the principal objectives and methods of sequen-
tial clinical trials have been described. The work presented
has been motivated by the natural attractions of stopping
trials as soon as the data are sufficient, and in response to
valid criticisms of the oversimplified nature of early attempts
to construct sequential designs. Problems still remain with
many types of clinical trial, including those with more than
two treatments and those in which the monitoring of more
than one endpoint is essential. (The analysis of more than
one endpoint in a trial stopped due to the monitoring ofjust
one of them is a different problem for which some limited
results are already available).
Despite the limitations mentioned above, sequential
methods do provide potential designs for a wide class of
clinical trials in cancer. Retrospective consideration of how
the methods would have affected completed trials has already
been made by Rosner and Tsiatis (1989) (see also Facey &
Whitehead, 1990), and by Donaldson et al. (1993). In both
papers a worthwhile reduction in sample size without a
change in trial conclusions was claimed. The development of
sequential methods has now reached the stage at which
extensive exploration of their use in cancer trials is appropri-
ate.
In this paper attention has been restricted to individual
clinical trials. Often more than one clinical trial of the same
novel treatment is considered necessary either to obtain regi-
stration of a drug or to alter clinical opinion and practice.
Here, conventional power requirements have been used to set
a flexible stopping rule rather than a rigid sample size. Issues
of what level of significance to specify and how to plan and
combine multiple clinical trials affect sequential and non-
sequential designs alike. Exciting new methodologies which
combine sequential concepts with those of meta-analysis will
be needed to decide when to stop performing new studies of
the same medical treatment, and how to monitor more than
one ongoing trial addressing the same therapeutic ques-
tion.
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Appendix: Survival probabilities and hazard ratios.
Denote by Pc and PE respectively, the percentages of patients
surviving for longer than six months on the control and experi-
mental treatments respectively. Denote the hazard ratio by HR.
Let the Greek letter 6 denote minus the (natural) logarithm of
HR. That is
6=-log HR. (1)
When hazards are proportional, 6 is also given by
6 = -log {-log (PE/100)) + log {-log (Pc/lOO)), (2)
where all logs are natural. In fact, 6 is given by equation (2)
whatever time period is specified, and not just for the case of '6
months' used above. This lack of dependence on the time period
is a consequence of the proportional hazards assumption.
For Pc = 50 and PE = 65, equation (2) gives 6 = 0.48, and for
HR = 0.62, equation (1) also gives 6 = 0.48 confirming the
equivalence of the specifications given in Section 2.